Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BATMAN: Alpha-1 Antitrypsin in Bronchiectasis
NCT05582798Phase 4Completed
- Sponsor
- University of Dundee
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alpha1-proteinase inhibitor in bronchiectasis (4 arms), sponsored by University of Dundee. Primary endpoint: Sputum Neutrophil Elastase Activity at 4 weeks. Started Nov 2022; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT05582798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582798.